Overview

• FDA authorization followed three clinical trials with over 500 participants showing once-daily Vizz improved near vision for up to 10 hours within 30 minutes of application.
• Vizz’s aceclidina ingredient induces a pinhole effect by constricting the pupil to under 2 millimeters, boosting depth of focus for close-up tasks.
• Trial data reported mostly mild and transient side effects, including ocular irritation in about 20% of users, dim vision in 16% and headaches in 13%.
• LENZ Therapeutics aims for general U.S. pharmacy availability in the fourth quarter of 2025 and is pursuing distribution partnerships in Canada and China.
• Ophthalmologists emphasize the need for post-marketing monitoring to assess real-world effectiveness, lighting dependence and long-term safety.